A review by Salah et al., which specifically addressed the initiation of SGLT2 inhibitors in patients hospitalized for AHF, demonstrated a significant reduction in the risk of rehospitalization for HF and improvement in patient-reported outcomes without an increase in adverse effects such as AKI, hypotension, or hypoglycemia. Here, SLC5A2 is linked to Hypoglycemia.